Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia.
JAMA Neurol. 2018 Jul 1;75(7):881-887. doi: 10.1001/jamaneurol.2018.0046.
Migraine is a disabling and prevalent condition that affects the pediatric and adolescent population. This review describes current acute and preventive migraine pharmacologic therapies for the pediatric and adolescent population.
Multiple pharmacotherapies that have been used in the treatment of acute headache and prevention in pediatric migraine are reviewed. There have been recent advances in the management of migraines among pediatric and adolescent patients, including US Food and Drug Administration approval of triptans for acute management in children as young as 6 years, and the first prospective, randomized, double-blind, placebo-controlled comparative study of preventive pharmacotherapy in pediatric migraine. A major challenge of evidence-based research in pediatric and adolescent migraine is the significant placebo effect.
Although progress is being made in the management of migraines among pediatric and adolescent patients, there remains much work to be done.
偏头痛是一种使人丧失能力且普遍存在的疾病,会影响儿童和青少年人群。本综述描述了目前针对儿童和青少年人群的偏头痛急性和预防性药物治疗。
本文回顾了多种已用于治疗儿童偏头痛急性发作和预防的药物疗法。在儿童和青少年偏头痛患者的管理方面,最近取得了一些进展,包括美国食品和药物管理局批准曲普坦类药物用于 6 岁及以上儿童的急性治疗,以及第一项针对儿童偏头痛预防药物治疗的前瞻性、随机、双盲、安慰剂对照比较研究。儿科和青少年偏头痛的循证研究的一个主要挑战是显著的安慰剂效应。
尽管在儿童和青少年偏头痛患者的管理方面正在取得进展,但仍有许多工作要做。